Acceptance rate of long‐acting injection after short information: a survey in patients with first‐ and multiple‐episode psychoses and their caregivers

Yeo, Seonguk; Park, Jong-Il; Jang, Jin-Mahn; Kang, Nam‐In; Cui, Yin; Kim, Min‐Gul; Kim, Hyun‐Min; Jung, Ae-Ja; Chung, Young‐Chul

doi:10.1111/eip.12262

Cited by 8 publications

(5 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prescription rate of LAIA was roughly 18-26% in the present study, which is considerably higher than the 15.3% reported for East Asian countries 73 and even the 3.3% rate reported for Korea 74 . Considering that LAIA acceptance rates have been reported at 32.7% for patients with FEP 75 and that psychiatrists offered antipsychotic depot treatment to only 35% of their patients suffering from SZ or schizoaffective disorder 76 , there seems to be more room for LAIA. It is of interest that relapse rates in PNOS were relatively higher compared to SZ.…”

Section: Discussionmentioning

confidence: 99%

Three-year outcomes and predictors for full recovery in patients with early-stage psychosis

Rami

Lee

et al. 2022

Schizophr

Self Cite

View full text Add to dashboard Cite

In the present study, various outcomes over 3-year period in patients with early stage psychosis including remission, recovery, relapse and medication adherence were investigated. Predictor for full recovery at year 3 was also examined. Three-year follow-up data in 534 patients with schizophrenia spectrum disorders (SSD) and psychotic disorder not otherwise specified (PNOS) were examined for overall outcome trajectories. The data of completers at year 3 (n = 157) were used to identify predictors for recovery using logistic regression. The rates of symptomatic remission and full recovery at 6-, 12-, 24-, and 36-month follow-up were 76.10, 69.20, 79.50, and 79.10%, and 22.80, 26.40, 28.60, and 39.60%, respectively. The rates of drop-out and relapse at 6-, 12-, 24-, and 36-month follow-up were 25.4, 29.5, 38.6, and 51.1%, and 3.7, 8.9, 19.0, and 38.9%, respectively. The rates of good adherence and prescription of Long-Acting Injectable Antipsychotics (LAIA) at 6-, 12-, 24- and 36-month follow-up were 87.8, 88.0, 91.9, and 93.9%, and 18.3, 21.7, 22.0, and 25.5%, respectively. Significant predictors for full recovery were duration of untreated psychosis (DUP), family intimacy and physical activity. We observed similar or better results on remission, recovery, and relapse rates compared to other previous studies. Effective psychosocial intervention should be provided to shorten the gap between remission and recovery rates and to address DUP, family issues, and exercise to enhance recovery.

show abstract

Section: Discussionmentioning

confidence: 99%

Three-year outcomes and predictors for full recovery in patients with early-stage psychosis

Rami

Lee

et al. 2022

Schizophr

Self Cite

View full text Add to dashboard Cite

show abstract

“…In this regard, the panel of experts agreed that LAI formulations should be preferred in non-adherent patients, especially considering the significant delay in the time to relapse when this treatment formulation is discontinued or withdrawn. Such a delay is likely to be appreciated by family members/caregivers of non-adherent patients, as it gives more time to persuade the patient to resume antipsychotic treatment 88. The reduced need of monitoring treatment adherence provides the following advantages: on one hand, the treatment team can focus on the patient’s personal goals with a consequent improvement of therapeutic alliance;49 on the other hand, patients and caregivers can reduce disputes about medication adherence, which may lead them to feel a sense of greater stability that can consequently restore a family climate of “normality” 37…”

Section: Discussionmentioning

confidence: 99%

“…Such a delay is likely to be appreciated by a non-adherent patient’s family members/caregivers, as it gives more time to persuade the patient to resume antipsychotic treatment. In fact, when asked whether they would have preferred the patient to be switched from the current oral antipsychotic formulation to a once-every-3-months LAI formulation, 67.5% of caregivers of first-episode patients and 77.8% of multiple-episode patients preferred the once-every-3-months formulation 88…”

Section: Adherence To Treatmentmentioning

confidence: 99%

<p>The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia</p>

Pietrini¹,

Albert²,

Ballerini³

et al. 2019

NDT

View full text Add to dashboard Cite

Schizophrenia is a chronic syndrome involving different clinical dimensions, and causes significant disability with a negative impact on the quality of life of patients and their caregivers. Current guidelines for the treatment of schizophrenia focus on maximizing a patient’s adaptive functioning and quality of life in a recovery-oriented approach that encourages active collaboration among patients, caregivers, and mental health professionals to design and manage a customized and comprehensive care plan. In the present study, a panel of experts (psychiatrists, psychologists, nurse, and social worker) gathered to review and explore the need for contemporary use of second-generation antipsychotic long-acting injectables (SGA LAIs) in “recovery-oriented” and “patient-centered” care of schizophrenia. Starting from the available data and from sharing personal attitudes and experiences, the panel selected three clinical dimensions considered useful in characterizing each patient: phase of disease, adherence to treatment, and level of functioning. For each clinical dimension, perspectives of patients and caregivers with regard to needs, expectations, and personal experiences were reviewed and the role of SGA LAIs in achieving shared goals examined. The experts concluded that from today’s modern perspectives, SGA-LAIs may play an important role in breaking the spiral of desocialization and functional decline in schizophrenia, thus favoring the recovery process.

show abstract

“…On the part of the patients, the refusal is related in particular to the mode of administration (injection), the control of the treatment (the feeling that they no longer decide), the administration protocols (in specialized centers, post injection monitoring in the case of olanzapine pamoate, etc.) (Yeo et al, 2017).…”

Section: Letter To the Editormentioning

confidence: 99%

Long-acting injectable antipsychotics treatment during COVID-19 pandemic – A new challenge

Ifteni

Dima

Teodorescu

2020

Schizophrenia Research

View full text Add to dashboard Cite

Acceptance rate of long‐acting injection after short information: a survey in patients with first‐ and multiple‐episode psychoses and their caregivers

Cited by 8 publications

References 23 publications

Three-year outcomes and predictors for full recovery in patients with early-stage psychosis

Three-year outcomes and predictors for full recovery in patients with early-stage psychosis

<p>The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia</p>

Long-acting injectable antipsychotics treatment during COVID-19 pandemic – A new challenge

Contact Info

Product

Resources

About